The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; none of the 34 sources its claims cite is checked for support yet.
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Open accessAbstract
BACKGROUND: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. METHODS: In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. In all the patients, disease had progressed during receipt of first-line EGFR-TKI therapy. The primary end point was investigator-assessed progression-free survival. RESULTS: The median duration of progression-free survival was significantly longer with osimertinib than with platinum therapy plus pemetrexed (10.1 months vs. 4.4 months; hazard ratio; 0.30; 95% confidence interval [CI], 0.23 to 0.41; P<0.001). The objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with platinum therapy plus pemetrexed (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001). Among 144 patients with metastases to the central nervous system (CNS), the median duration of progression-free survival was longer among patients receiving osimertinib than among those receiving platinum therapy plus pemetrexed (8.5 months vs. 4.2 months; hazard ratio, 0.32; 95% CI, 0.21 to 0.49). The proportion of patients with adverse events of grade 3 or higher was lower with osimertinib (23%) than with platinum therapy plus pemetrexed (47%). CONCLUSIONS: Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced non-small-cell lung cancer (including those with CNS metastases) in whom disease had progressed during first-line EGFR-TKI therapy. (Funded by AstraZeneca; AURA3 ClinicalTrials.gov number, NCT02151981 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 34 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On the basis of investigator assessment, the median response duration was 9.7 months (95% CI, 8.3 to 11.6) in the osimertinib group and 4.1 months (95% CI, 3.0 to 5.6) in the platinum–pemetrexed group.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with platinum therapy plus pemetrexed (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).”
- Also stated in: § EFFICACY · plain
“The response rate was significantly better in the osimertinib group (71%; 95% CI, 65 to 76) than in the platinum–pemetrexed group (31%; 95% CI, 24 to 40) (odds ratio, 5.39; 95% CI, 3.47 to 8.48; P<0.001) (Table 2).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § EFFICACY · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Improvement in outcomes with osimertinib over platinum–pemetrexed in the tumor and plasma ctDNA T790M-positive subgroup was similar to that in the intention-to-treat population.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most commonly reported adverse events in the platinum–pemetrexed group were nausea (in 67 patients [49%]), decreased appetite (in 49 [36%]), constipation (in 47 [35%]), and anemia (in 41 [30%]).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
Strength:plain· not yet calibratedn = 67Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of patients with adverse events of grade 3 or higher was lower with osimertinib (23%) than with platinum therapy plus pemetrexed (47%).”
- Also stated in: § SAFETY AND ADVERSE EVENTS · plain
“Fewer patients reported adverse events of grade 3 or more in the osimertinib group than in the platinum–pemetrexed group (63 [23%] vs. 64 [47%]).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > RESULTS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § SAFETY AND ADVERSE EVENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In a mixed model for repeated-measures analysis, patient-reported outcomes were better in the osimertinib group than in the platinum–pemetrexed group across five prespecified symptoms during the overall period from randomization until 6 months (Table S4 in the Supplementary Appendix).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A similar finding was observed in the subgroup of patients with T790M-positive status on both tumor and plasma analyses (89 of 116 patients [77%] vs. 22 of 56 patients [39%]; odds ratio, 4.96; 95% CI, 2.49 to 10.15; P<0.001).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Osimertinib was associated with a lower rate of adverse events leading to permanent discontinuation than was platinum–pemetrexed (in 19 patients [7%] and 14 patients [10%], respectively).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of progression-free survival among patients with tumor and plasma T790M-positive status was 8.2 months in the osimertinib group versus 4.2 months in the platinum–pemetrexed group (hazard ratio, 0.42; 95% CI, 0.29 to 0.61) (Fig. 1C).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fatal adverse events were reported in 4 patients in the osimertinib group (respiratory failure in 2, pneumonitis in 1, and ischemic stroke in 1). One fatal adverse event of hypovolemic shock was reported in the platinum–pemetrexed group.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
Strength:plain· not yet calibratedn = 4Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- It may state two separate claims as one. 12
- Probably not a substantial claim. 7
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A prolongation in the QT interval was recorded in 10 patients (4%) in the osimertinib group and 1 patient (1%) in the platinum–pemetrexed group, with all events of grade 1 or 2 in severity except for one grade 3 event in the osimertinib group.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
Strength:plain· not yet calibratedn = 10Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The hazard ratio for progression-free survival favored osimertinib across all predefined subgroups that were analyzed (hazard ratio, <0.50 for each subgroup) (Fig. 2), including patients with CNS metastases (median duration of progression-free survival, 8.5 months vs. 4.2 months; hazard ratio, 0.32; 95% CI, 0.21 to 0.49) (Fig. 1B).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The duration of progression-free survival according to blinded independent central review was consistent with the investigator-assessed durations, with a median of 11.0 months versus 4.2 months (adjusted hazard ratio, 0.28; 95% CI, 0.20 to 0.38; P<0.001).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interstitial lung disease–like adverse events were reported in 10 patients (4%) in the osimertinib group (nine events of grade 1 or 2 in severity and one death) and in 1 patient (1%) in the platinum–pemetrexed group (one grade 3 event).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
Strength:plain· not yet calibratedn = 10Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the patients who underwent randomization were included in the intention-to-treat population, which was used for all efficacy analyses.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > STATISTICAL ANALYSIS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, adverse events tended to be more severe in the platinum–pemetrexed group, despite the longer treatment duration with osimertinib.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > DISCUSSION
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The safety analysis included all the patients in the intention-to-treat population who had received at least one dose of a trial drug and for whom data were available after the administration of the drug.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > STATISTICAL ANALYSIS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The presence of the T790M variant reduces binding of first-generation or second-generation EGFR-TKIs to the ATP-binding pocket of EGFR, thereby reducing EGFR-TKI–mediated inhibition of downstream signaling and potentially leading to disease progression.17–19”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [17] Yun CH, Mengwasser KE, Toms AV, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008; 105: 2070– 5. 18227510 PMC2538882 source
- Not checked yetcites [18] Sos ML, Rode HB, Heynck S, Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 2010; 70: 868– 74. 20103621 source
- Not checked yetcites [19] Cross DA, Ashton SE, Ghiorghiu S, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046– 61. 24893891 PMC4315625 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“These findings were confirmed in a pooled analysis of two subsequent phase 2 studies of osimertinib (at a dose of 80 mg once daily) in 411 patients with T790M-positive non–small-cell lung cancer, in which the response rate was 66% on blinded independent central review and the median duration of progression-free survival was 11.0 months.23”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [23] Yang J, Ramalingam SS, Jänne PA, Cantarini M, Mitsudomi T. LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol 2016; 11: Suppl: S152– S153. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines (as defined by the International Conference on Harmonisation), applicable regulatory requirements, and the policy on bioethics and human biologic samples of the trial sponsor, AstraZeneca.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > TRIAL OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We determined that 221 events of progression or death would provide a power of 80% to reject the null hypothesis of no significant difference in the duration of progression-free survival between the two treatment groups, assuming a treatment effect hazard ratio of 0.67 with a P value of 0.05 indicating two-sided statistical significance.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > STATISTICAL ANALYSIS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Osimertinib is an oral, irreversible EGFR-TKI that is selective for both EGFR and T790M resistance mutations with activity in the central nervous system (CNS).19–21”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [19] Cross DA, Ashton SE, Ghiorghiu S, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046– 61. 24893891 PMC4315625 source
- Not checked yetcites [20] Ballard P, Yates JW, Yang Z, Pre-clinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 2016; 22: 5130– 40. 27435396 source
- Not checked yetcites [21] Yang JC-H, Kim D-W, Kim S-W, Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I study. J Clin Oncol 2016; 34: Suppl: 9002 abstract. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Among patients with advanced non–small-cell lung cancer with a mutant epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line therapy.1–4”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [1] Masters GA, Temin S, Azzoli CG, Systemic therapy for Stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2015; 33: 3488– 515. 26324367 PMC5019421 source
- Not checked yetcites [2] Novello S, Barlesi F, Califano R, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: Suppl 5: v1– v27. 27664245 source
- Not checked yetcites [3] Tan DS, Yom SS, Tsao MS, The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016. J Thorac Oncol 2016; 11: 946– 63. 27229180 source
- Not checked yetcites [4] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: NSCLC (version 3.2017). 2016 (http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). 28188192 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A sensitivity analysis of progression-free survival by blinded independent central review was conducted.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > TRIAL END POINTS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients were stratified according to Asian or non-Asian race and were randomly assigned in a 2:1 ratio to receive oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > TRIAL DESIGN AND TREATMENT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In AURA3, the safety profile for osimertinib was consistent with that reported previously and differed from that in the platinum–pemetrexed group.23”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > DISCUSSION
What the sources say
- Not checked yetcites [23] Yang J, Ramalingam SS, Jänne PA, Cantarini M, Mitsudomi T. LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol 2016; 11: Suppl: S152– S153. source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In the phase 1 component of AURA, a phase 1/2 trial (ClinicalTrials.gov number, ), the objective response rate for osimertinib in patients with T790M-positive non–small-cell lung cancer was 61%; the median duration of progression-free survival was 9.6 months.22”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [22] Jänne PA, Yang JC-H, Kim D-W, AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer. N Engl J Med 2015; 372: 1689– 99. 25923549
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
Platinum-pemetrexed was the standard of care for patients with T790M-positive advanced NSCLC after first-line EGFR-TKI at the time of trial initiation.
“Chemotherapy was the standard control at the time of trial initiation.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In T790M-positive tumors, following progression after first- or second-generation EGFR TKIs, second-line osimertinib has demonstrated significant efficacy compared with chemotherapy (median PFS: 10.1 vs 4.4 months; HR, 0.30 (95% CI, 0.23‒0.40), P < 0.001).”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [48]
Experimental — accuracy not yet measuredIn the citing paper
“In addition to being used alone, osimertinib is also being studied in combination with other targeted therapies for NSCLC, such as inhibitors of the Met, Bcl-2, and MAPK pathways.138–140”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [140]
In the citing paper
“Even more variable are duration of response to targeted therapy, progression-free survival and overall survival16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [21]
In the citing paper
“Across clinical trials of first-line targeted therapy for oncogene-addicted subgroups of NSCLC, rates of objective response [G] typically range between 50% and 83% and complete responses [G] are rare; in addition, some patients exhibit de novo resistance16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [21]
In the citing paper
“In a randomized phase III trial[3], osimertinib significantly improved both progression-free survival (PFS) and objective response rate (ORR) when compared to platinum-pemetrexed chemotherapy for T790M-positive non-small cell lung cancer (NSCLC) after progression on 1st or 2nd generation EGFR-TKIs.”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [3]
In the citing paper
“In the AURA3 phase III trial, osimertinib demonstrated signi fi cantly higher ef fi cacy than platinum-based chemotherapy in patients with T790M-positive NSCLC. 14”
From Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) (2020) · cites this paper as [14]
In the citing paper
“Osimertinib was granted accelerated approval by the FDA in 2015 as a second-line treatment for NSCLC, and was approved as a first-line treatment for metastatic NSCLC in 2018 (ref.49).”
From Advances in covalent drug discovery (2022) · cites this paper as [49]
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationGefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationNovello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Flagged first, then by citations
Research works printed but not linked: 1
- Soria J, 2015, J Thorac Oncol, 10, S207
Cited by
Sorted by citations
Items 901–1,000 of 1,003
Targeted Therapy for Non-Small Cell Lung Cancer
Noor, Z. S., Cummings, A. L., Johnson, M. M., Spiegel, M. L., & Goldman, J. W. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1700994 · Cited by 27
Hu, X., Chen, S., Yin, H., Wang, Q., Duan, Y., Jiang, L., & Zhao, L. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.154 · Cited by 29
erbB in NSCLC as a molecular target: current evidences and future directions
Re, M. D., Cucchiara, F., Petrini, I., Fogli, S., Passaro, A., Crucitta, S., Attili, I., de Marinis, F., Chella, A., & Danesi, R. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000724 · Cited by 29
John, C., Bello, R. D., Andratschke, N. H., Gückenberger, M., Boda‐Heggemann, J., Gkika, E., Mantel, F., Specht, H. M., Stromberger, C., Zehentmayr, F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83210-3 · Cited by 27
Han, R., Jia, Y., Li, X., Zhao, C., Zhao, S., Liu, S., Liu, Y., Chen, D., Zhang, Q., Liu, X., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1153 · Cited by 27
Scalvini, L., Castelli, R., Monica, S. L., Tiseo, M., & Alfieri, R. R. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114643 · Cited by 28
Zhai, X., Li, W., Li, J., Jia, W., Wang, J., Tian, Y., Xu, S., Li, Y., Zhu, H., & Yu, J. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01955-7 · Cited by 27
Lü, S., Zhang, Y., Zhang, G., Zhou, J., Cang, S., Cheng, Y., Wu, G., Cao, P., Lv, D., Jian, H., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.06.002 · Cited by 27
Sanchez‐Burgos, L., Navarro‐González, B., García‐Martín, S., Sirozh, O., Mota‐Pino, J., Fueyo‐Marcos, E., Tejero, H., Antón, M. E., Murga, M., Al‐Shahrour, F., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215855 · Cited by 27
Histologic transformation in lung cancer: when one door shuts, another opens
Sato, Y., Saito, G., & Fujimoto, D. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221130503 · Cited by 27
Villaruz, L., Wang, X., Bertino, E. M., Gu, L., Antonia, S. J., Burns, T. F., Clarke, J. M., Crawford, J., Evans, T. L., Friedland, D., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101183 · Cited by 27
Yu, H. A., Yang, J. C., Hayashi, H., Goto, Y., Felip, E., Reck, M., Vigliotti, M., Dong, Q., Cantero, F., Fan, P., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-1250 · Cited by 29
Sharma, M., Basu, D. A., Nathany, S., Amrith, B. P., & Batra, U. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_222_22 · Cited by 28
Kinase-Centric Computational Drug Development
Kooistra, A. J., & Volkamer, A. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.001 · Cited by 27
Zheng, X. X., Wang, W., Zhang, Y., Ma, Y., Zhao, H., Hu, P., & Jiang, J. (2018) · Biomedical Chromatography · doi:10.1002/bmc.4365 · Cited by 27
Zhang, J., Zhang, Y., Tang, S., Jiang, L., He, Q., Hamblin, L. T., He, J., Wu, J., Wu, J., Chen, Y., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-017240 · Cited by 27
Zhang, Y., Zhou, Q. H., & Wu, Y.-L. L. C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.044 · Cited by 27
Self-citationKim, Y., Shin, S., Kim, B., & Lee, K. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0978-8 · Cited by 27
Romero, A., Lewintre, E. J., García‐Peláez, B., Royuela, A., Insa, A., Cruz, P., Collazo-Lorduy, A., Altozano, J. P., Juan, Ó., Díz, P., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12832 · Cited by 27
Combination Therapy for EGFR -Mutated Lung Cancer
Wu, Y.-L. L. C., & Zhou, Q. H. (2023) · New England Journal of Medicine · doi:10.1056/nejme2311559 · Cited by 27
Self-citationShi, Y., Zhao, Y., Yang, S., Zhou, J., Zhang, L., Chen, G., Fang, J., Zhu, B., Li, X., Shu, Y., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.01.015 · Cited by 27
Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines
Grabe, T., Jeyakumar, K., Niggenaber, J., Schulz, T., Koska, S., Kleinboelting, S., Beck, M. E., Müller, M. P., & Rauh, D. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00514 · Cited by 26
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Mina, S. A., Shanshal, M., Leventakos, K., & Parikh, K. (2025) · Cancers · doi:10.3390/cancers17030353 · Cited by 27
Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma
Shinozaki, T., Togasaki, K., Hamamoto, J., Mitsuishi, A., Fukushima, T., Sugihara, K., Ebisudani, T., Okada, M., Saito, A., Shigematsu, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59623-3 · Cited by 26
Borgeaud, M., Olivier, T., Bar, J., Saw, S. P. L., Parikh, K., Banna, G. L., Vito, C. D., Feldman, J., Le, X., & Addeo, A. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70024 · Cited by 34
The role of circulating free DNA in the management of NSCLC
Abate, R. E., Pasquale, R., Fenizia, F., Rachiglio, A. M., Roma, C., Bergantino, F., Forgione, L., Lambiase, M., Sacco, A., Piccirillo, M. C., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1548938 · Cited by 26
Karim, N. A., & Kelly, K. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0112 · Cited by 26
Maso, A. D., Lorenzi, M., Roca, E., Pilotto, S., Macerelli, M., Polo, V., Cecere, F. L., Conte, A. D., Nardo, G., Buoro, V., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.07.009 · Cited by 26
Role of Next-Generation Sequencing Technologies in Personalized Medicine
Morganti, S., Tarantino, P., Ferraro, E., D’Amico, P., Viale, G., Trapani, D., Duso, B. A., & Curigliano, G. (2019) · Springer eBooks · doi:10.1007/978-3-030-27994-3_8 · Cited by 30
Targeting MET in EGFR resistance in non-small-cell lung cancer—ready for daily practice?
Schmid, S., Früh, M., & Peters, S. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30859-9 · Cited by 26
Romero, A., Serna‐Blasco, R., Alfaro, C., Sánchez‐Herrero, E., Barquín, M., Turpín, M. C., Chico, S., Sanz‐Moreno, S., Rodríguez-Festa, A., Briviesca, R. L., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.04.01 · Cited by 26
Melosky, B. L., Banerji, S. O., Blais, N., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., Liu, G., & Cheema, P. K. (2020) · Current Oncology · doi:10.3747/co.27.6007 · Cited by 27
Du, T., Li, X., Zhong, W.-S., Tian, J.-D., Zhao, Y., & Liu, D. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03359-8 · Cited by 26
Gai, W., Zhou, Z., Agbor-Enoh, S. T., Fan, X., Lian, S., Jiang, P., Cheng, S. H., Wong, J., Chan, S. L., Jang, M. K., et al. (2021) · eLife · doi:10.7554/elife.64356 · Cited by 26
Nana, F. A., & Ocak, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091478 · Cited by 26
Jünger, S. T., Reinecke, D., Meißner, A.-K., Goldbrunner, R., & Grau, S. (2021) · Journal of neurosurgery · doi:10.3171/2021.7.jns211172 · Cited by 27
Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
Wiest, N. E., Majeed, U., Seegobin, K., Zhao, Y., Lou, Y., & Manochakian, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751209 · Cited by 26
Peled, N., Kian, W., Inbar, E., Goldstein, I. M., Zemel, M., Rotem, O., Rozenblum, A. B., Nechushtan, H., Dudnik, E., Levin, D., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab188 · Cited by 27
Kim, B., Kim, Y., Shin, S., Lee, S., Choi, Y., & Lee, K. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02504-2 · Cited by 26
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors
Kobayashi, Y., Oxnard, G. R., Cohen, E. F., Mahadevan, N. R., Alessi, J. V., Hung, Y. P., Bertram, A. A., Heppner, D. E., Ribeiro, M. F. S. A., Sacardo, K. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33210-2 · Cited by 26
Bylicki, O., Tomasini, P., Gervais, R., Guisier, F., Monnet, I., Ricordel, C., Bigay-Game, L., Geier, M., CHOUAID, C., Daniel, C., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.014 · Cited by 26
Li, M., Coumar, M. S., Lin, S., Lin, Y., Huang, G., Chen, C.-H., Lien, T., Wu, Y., Chen, Y., Chen, C.-P., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01434 · Cited by 26
Self-citationWatanabe, S., Furuya, N., Nakamura, A., Shiihara, J., Nakachi, I., Tanaka, H., Nakao, M., Minato, K., Seike, M., Sasaki, S., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113469 · Cited by 26
Han, R., Guo, H., Shi, J., Zhao, S., Jia, Y., Liu, X., Liu, Y., Cheng, L., Zhao, C., Li, X., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03389-w · Cited by 27
Yamamoto, G., Kikuchi, M., Kobayashi, S., Arai, Y., Fujiyoshi, K., Wakatsuki, T., Kakuta, M., Yamane, Y., Iijima, Y., Mizutani, H., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3935 · Cited by 26
Gaut, D. L., Sim, M., Yue, Y., Wolf, B. R., Abarca, P. A., Carroll, J., Goldman, J. W., & Garon, E. B. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.004 · Cited by 26
Satoh, S., Shiroyama, T., Tamiya, M., Nasu, S., Tanaka, A., Morita, S., Morishita, N., Suzuki, H., Okamoto, N., & Hirashima, T. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.12.005 · Cited by 26
Igawa, S., Ono, T., Kasajima, M., Ishihara, M., Hiyoshi, Y., Kusuhara, S., Nishinarita, N., Fukui, T., Kubota, M., Sasaki, J., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s207170 · Cited by 26
Genova, C., Rossi, G., Tagliamento, M., Rijavec, E., Biello, F., Cerbone, L., Zullo, L., & Grossi, F. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1714441 · Cited by 27
Hsiao, T., Wang, C., Wu, Y., Feng, H., Chiu, Y., Lin, H.-Y., Liu, K., Chang, G., Chien, K., Yu, J.-S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3972 · Cited by 26
Self-citationTackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
Pacini, L., Jenks, A. D., Vyse, S., Wilding, C. P., Arthur, A., & Huang, P. H. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s242045 · Cited by 27
Xu, J., Wu, W., Wu, C., Mao, Y., Qi, X., Guo, L., Lu, R., Xie, S., Lou, J., Zhang, Y., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-564 · Cited by 26
Lim, S. M., Schalm, S. S., Lee, E. J., Park, S., Conti, C., Millet, Y. A., Woessner, R., Zhang, Z., Tavera-Mendoza, L. E., Stevison, F., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241280689 · Cited by 26
Tumor-Agnostic Therapies in Practice: Challenges, Innovations, and Future Perspectives
Wu, S., & Thawani, R. (2025) · Cancers · doi:10.3390/cancers17050801 · Cited by 26
Alsaed, B., Bobik, N., Laitinen, H. K., Nandikonda, T., Ilonen, I., & Haikala, H. M. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10272-4 · Cited by 25
Aref‐Eshghi, E., Abadi, A., Farhadieh, M., Hooshmand, A., Ghasemi, F., Youssefian, L., Vahidnezhad, H., Kerrins, T. M., Zhao, X., Akbarzadeh, M., et al. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01967-0 · Cited by 26
Proteoform medicine: characterizing and targeting protein forms in human disease
Korchak, J. A., Yi, S. S., Kelleher, N. L., Sahni, N., & Sheynkman, G. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-025-00915-1 · Cited by 26
The efficacy and safety of osimertinib in treating nonsmall cell lung cancer
Liu, J., Li, X., Shao, Y., Guo, X., & He, J. (2020) · Medicine · doi:10.1097/md.0000000000021826 · Cited by 25
Lee, K., Kim, D., Yoon, S., Lee, K. H., & Kim, S. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.052 · Cited by 25
Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review
Caputo, A., D’Ardia, A., Sabbatino, F., Picariello, C., Ciaparrone, C., Zeppa, P., & D’Antonio, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094852 · Cited by 25
CHOUAID, C., Filleron, T., Debieuvre, D., Pérol, M., Girard, N., Dansin, É., Léna, H., Gervais, R., Cousin, S., Otto, J., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00848-9 · Cited by 25
Haratake, N., Hayashi, H., Shimokawa, M., Nakano, Y., Azuma, K., Oki, M., Ota, K., Yoshioka, H., Sakamoto, T., Yamamoto, N., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.10.007 · Cited by 25
Systemic Therapy for Lung Cancer Brain Metastases
Pellerino, A., Bruno, F., Rudà, R., & Soffietti, R. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00911-7 · Cited by 26
Nadler, E., Vasudevan, A., Wang, Y., & Ogale, S. S. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100522 · Cited by 25
Fu, Z., Li, S., Liu, J., Zhang, C., Chen, J., Wang, L., Zhang, Y., & Chen, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.847906 · Cited by 25
Wu, S., Sun, Z., Guo, Z., Li, P., Mao, Q., Tang, Y., Chen, H., Peng, H., Wang, S., & Cao, Y. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116565 · Cited by 25
Thress, K. S., Jacobs, V. N., Angell, H. K., Yang, J. C., Sequist, L. V. D., Blackhall, F. H., Su, W., Schüler, M., Wolf, J., Gold, K. A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.011 · Cited by 25
Koh, K. X., Tan, G. H., Low, S. H. H., Omar, M. F. M., Han, M. J., Iacopetta, B. J., Soo, R. A., Beloueche‐Babari, M., Bhattacharya, B., & Soong, R. (2017) · Oncotarget · doi:10.18632/oncotarget.22655 · Cited by 25
Ghafoor, Q., Baijal, S., Taniere, P., O’Sullivan, B., Evans, M., & Middleton, G. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0377-1 · Cited by 25
Cagney, D. N., Martin, A. M., Catalano, P. J., Reitman, Z. J., Mezochow, G. A., Lee, E. Q., Wen, P. Y., Weiss, S. E., Brown, P. D., Ahluwalia, M. S., et al. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.01.005 · Cited by 25
Zhang, B., Wang, S., Qian, J., Yang, W., Qian, F., Lü, J., Zhang, Y., Qiao, R., & Han, B. (2018) · Cancer · doi:10.1002/cncr.31329 · Cited by 26
O'Kane, G. M., Barnes, T. A., & Leighl, N. B. (2018) · Current Oncology · doi:10.3747/co.25.3796 · Cited by 25
Tian, P., Wang, Y., Wang, W., Li, Y., Wang, K., Cheng, X., Tang, Y., Han‐Zhang, H., Ye, J., Chuai, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.08.014 · Cited by 25
Lin, T., Tseng, A.-J., Qiu, W.-L., Chao, C., & Lu, M. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.01.078 · Cited by 25
Yang, S., Mao, S., Li, X., Zhao, C., Liu, Q., Yu, X., Wang, Y., Liu, Y., Pan, Y., Wang, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.11.018 · Cited by 26
Self-citationNakashima, K., Ozawa, Y., Daga, H., Imai, H., Tamiya, M., Tokito, T., Kawamura, T., Akamatsu, H., Tsuboguchi, Y., Takahashi, T., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00943-0 · Cited by 25
Self-citationBatra, U., Sharma, M., Amrith, B. P., Mehta, A., & Jain, P. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.05.016 · Cited by 25
Kang, M.-S., Park, C., Kim, S. H., Yoon, S. W., Suh, K. J., Kim, Y. J., Ock, C.-Y., Kim, M., Keam, B., Kim, T. M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-893 · Cited by 26
Zhang, D., Liu, X., Shen, F., Zhao, D., Shi, Y., Zhang, H., Liu, J., Gao, X., Chen, M., Zhao, J., et al. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-577 · Cited by 24
Joo, J. W., Hong, M. H., & Shim, H. S. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.04.013 · Cited by 24
Jiang, T., Zhao, J., Zhao, C., Li, X., Shen, J., Zhou, J., Ren, S., Su, C., Zhou, C., & O'Brien, M. E. R. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.11.014 · Cited by 24
Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing
Prabhash, K., Advani, S. H., Batra, U., Biswas, B., Chougule, A., Ghosh, M., Muddu, V. K., Sahoo, T. P., & Vaid, A. K. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00903-y · Cited by 24
Hong, M. H., Kim, H. R., Ahn, B., Heo, S. J., Kim, J. H., & Cho, B. C. (2019) · Yonsei Medical Journal · doi:10.3349/ymj.2019.60.6.525 · Cited by 24
Self-citationNovel molecular targets for the treatment of lung cancer
Rosell, R., Karachaliou, N., & Arrieta, O. G. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000590 · Cited by 24
Rajurkar, S. P., Mambetsariev, I., Pharaon, R. R., Leach, B., Tan, T., Kulkarni, P., & Salgia, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061870 · Cited by 25
The Role of Stereotactic Biopsy in Brain Metastases
Yu, K. K. H., Patel, A., & Moss, N. S. (2020) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2020.06.002 · Cited by 26
Kato, R., Hayashi, H., Sakai, K., Suzuki, S., Haratani, K., Takahama, T., Tanizaki, J., Nonagase, Y., Tanaka, K., Yoshida, T., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01947-3 · Cited by 24
Yu, X., Li, J., Ye, L., Zhao, J., Xie, M., Zhou, J., Shen, Y., Zhou, F., Wu, Y., Han, C., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-681 · Cited by 25
Self-citationNovel targeted therapies for advanced non-small lung cancer
Abughanimeh, O. K. M., Kaur, A., Osta, B. E. E., & Ganti, A. K. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.03.003 · Cited by 26
Chang, J. Y., & Verma, V. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7117 · Cited by 24
Kitadai, R., & Okuma, Y. (2022) · Cancers · doi:10.3390/cancers14102519 · Cited by 24
Lazertinib: on the Way to Its Throne
Lee, J., Hong, M. H., & Cho, B. C. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.9.799 · Cited by 24
Li, S., Zhu, S., Wei, H., Zhu, P., Jiao, Y., Yi, M., Gong, J., Zheng, K., & Zhang, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113959 · Cited by 26
Hu, X., Zhang, S., Ma, Z., Feng, J., Wu, L., Lv, D., Zhou, J., Zhang, X., Liu, L., Yu, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02865-z · Cited by 26
Retreatment With Osimertinib Following Pneumonitis
Nagasaka, M., & Gadgeel, S. M. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.017 · Cited by 24
Albaba, H., Lim, C. H., & Leighl, N. B. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0563-8 · Cited by 24
Le‐Rademacher, J. G., Dahlberg, S. E., Lee, J. J., Adjei, A. A., & Mandrekar, S. J. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2019 · Cited by 24
Oda, N., Hotta, K., Ninomiya, K., Minami, D., Ichihara, E., Murakami, T., Yokoyama, T., Ichikawa, H., Chikamori, K., Takigawa, N., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3694-5 · Cited by 24
Treatment of older patients with advanced non-small cell lung cancer: A challenge
Decoster, L., & Schallier, D. C. C. (2018) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2018.09.008 · Cited by 24
Nakao, A., Hiranuma, O., Uchino, J., Sakaguchi, C., Kita, T., Hiraoka, N., Ishizuka, T., Kubota, Y., Kawasaki, M., Gotô, Y., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0003 · Cited by 24
Metadata
- Authors
- Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., Lee, C. K., Sebastian, M., Templeton, A., Mann, H., Marotti, M., Ghiorghiu, S., & Papadimitrakopoulou, V. A.
- Affiliations
- Army Medical University (CN)
- Emory University (US)
- Goethe University Frankfurt (DE)
- AstraZeneca (United Kingdom) (GB)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-02-16
- Volume
- 376
- Issue
- 7
- Pages
- 629-640
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6762027
- OpenAlex
- W2560717039
- Semantic Scholar
- bd8840946a65bec6d407a96092eda55497e49a58
- Cited by
- 3,379
- References
- 25
- Citations by year
- 2026: 198 · 2025: 280 · 2024: 301 · 2023: 318 · 2022: 410 · 2021: 438 · 2020: 404 · 2019: 365 · 2018: 389 · 2017: 268
- FWCI
- 305.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Research Explorer (The University of Manchester) (submittedVersion, other-oa)
- Funders
- Cancer Research UK (20465)
- National Cancer Institute (P30CA016672)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- osimertinib, T790M mutation, non-small cell lung cancer, EGFR tyrosine kinase inhibitor resistance, pemetrexed, carboplatin, cisplatin, second-line therapy, progression-free survival, central nervous system metastasis, brain metastases, objective response rate, adverse events
- MeSH terms
- Pemetrexed, Acrylamides, Adult, Aged, Aged, 80 and over, Aniline Compounds, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Piperazines, Platinum, Pyrimidines, Disease-Free Survival, Young Adult, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
